Melissa Sharon*
Large Vessel Vasculitis (LVV) encompasses a group of inflammatory disorders primarily affecting the aorta and its major branches, including Giant Cell Arteritis (GCA) and Takayasu Arteritis (TA). Despite advancements in treatment, management of LVV remains challenging due to relapses, glucocorticoid dependency, and treatment-related adverse effects. This article explores novel therapeutic targets and emerging treatment strategies for LVV, including immunomodulatory agents, targeted biologic therapies, and small molecule inhibitors. By elucidating the underlying pathophysiological mechanisms and investigating innovative treatment approaches, healthcare providers can optimize outcomes and improve quality of life for patients with LVV.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 